| |
Vacc + & Sym+
|
Vacc + & Sym-
|
Vacc- & Sym+
|
Vacc- & Sym-
|
|---|
| |
A
|
C
|
P
|
A
|
C
|
P
|
A
|
C
|
p
|
A
|
C
|
P
|
|---|
| |
SRH (mm
2
), geometric mean
|
|
A/H1N1/California
|
20.6
|
28.7
|
<0.001
|
20.4
|
28.2
|
<
0.001
|
14.8
|
18.1
|
0.4
|
20.4
|
20.7
|
0.9
|
| |
IFN-γ (pg/mL)
|
|
A/H1N1/Brisbane
|
126
|
339
|
<0.001
|
115
|
279
|
<0.001
|
156
|
163
|
0.2
|
128
|
158
|
0.04
|
|
A/H1N1/Solomon s/3/2006
|
97
|
293
|
<0.001
|
90
|
231
|
<0.001
|
121
|
164
|
0.2
|
108
|
140
|
0.001
|
|
A/H3N2/Uruguay
|
195
|
350
|
<0.001
|
162
|
297
|
<0.001
|
224
|
256
|
0.3
|
170
|
233
|
<0.01
|
|
A/H3N2/Wisconsin
|
207
|
346
|
<0.001
|
170
|
294
|
<0.001
|
247
|
264
|
0.4
|
200
|
245
|
0.04
|
|
A/H5N1/Vietnam
|
346
|
426
|
0.03
|
325
|
427
|
<0.001
|
336
|
382
|
0.3
|
347
|
363
|
0.7
|
|
B/Florida
|
231
|
316
|
0.04
|
202
|
230
|
0.06
|
280
|
286
|
0.8
|
230
|
267
|
0.09
|
|
B/Malaysia
|
138
|
204
|
0.03
|
129
|
163
|
<0.01
|
191
|
221
|
0.4
|
157
|
183
|
0.1
|
|
M1
|
31
|
81
|
<0.01
|
27
|
51
|
<0.001
|
37
|
26
|
0.3
|
30
|
36
|
0.5
|
|
M2
|
18
|
18
|
0.3
|
18
|
20
|
0.03
|
18
|
18
|
0.3
|
18
|
20
|
0.5
|
|
CFP-10
|
21
|
19
|
0.3
|
22
|
24
|
0.4
|
18
|
18
|
0.9
|
21
|
22
|
0.5
|
|
PHA
|
513
|
521
|
0.3
|
495
|
513
|
0.05
|
500
|
546
|
0.15
|
516
|
534
|
0.3
|
|
Mean IFN-γ
|
165
|
240
| |
151
|
211
| |
173
|
199
| |
164
|
192
| |
|
N
|
69
|
69
| |
312
|
312
| |
48
|
48
| |
208
|
208
| |
- The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values (difference between time point A and B). Note the increased antigen-specific cellular immune responses in blood from participants who did not receive the vaccine and did not report any ILI symptoms. P values below 0.05 are indicated in bold.
